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STUDY QUESTION: Do changes in the expression of bone morphogenetic proteins (BMPs) 2 and 4, and their antagonists Gremlin1
(GREM1) and Gremlin2 (GREM2) during human fetal ovarian development impact on BMP pathway activity and lead to changes in gene
expression that may influence the fate and/or function of ovarian somatic cells?
STUDY FINDING: BMPs 2 and 4 differentially regulate gene expression in cultured human fetal ovarian somatic cells. Expression of some,
but not all BMP target genes is antagonised by GREM1 and GREM2, indicating the existence of a mechanism to fine-tune BMP signal intensity
in the ovary. Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), a marker of immature ovarian somatic cells, is identified as
a novel transcriptional target of BMP4.
WHAT IS KNOWN ALREADY: Extensive re-organisation of the germ and somatic cell populations in the feto-neonatal ovary culminates
in the formation of primordial follicles, which provide the basis for a female’s future fertility. BMP growth factors play important roles at many
stages of ovarian development and function. GREM1, an extracellular antagonist of BMP signalling, regulates the timing of primordial follicle
formation in the mouse ovary, and mRNA levels of BMP4 decrease while those of BMP2 increase prior to follicle formation in the human fetal
ovary.
STUDY DESIGN, SAMPLES/MATERIALS, METHODS: Expression of genes encoding BMP pathway components, BMP antagonists
and markers of ovarian somatic cells were determined by quantitative (q)RT-PCR in human fetal ovaries (from 8 to 21 weeks gestation) and
fetal ovary-derived somatic cell cultures. Ovarian expression of GREM1 protein was confirmed by immunoblotting. Primary human fetal ovar-
ian somatic cell cultures were derived from disaggregated ovaries by differential adhesion and cultured in the presence of recombinant human
BMP2 or BMP4, with or without the addition of GREM1 or GREM2.
MAIN RESULTS AND THE ROLE OF CHANCE: We demonstrate that the expression of BMP antagonists GREM1, GREM2 and
CHRD increases in the lead-up to primordial follicle formation in the human fetal ovary, and that the BMP pathway is active in cultured ovarian
somatic cells. This leads to differential changes in the expression of a number of genes, some of which are further modulated by GREM1 and/
or GREM2. The positive transcriptional regulation of LGR5 (a marker of less differentiated somatic cells) by BMP4 in vitro suggests that increas-
ing levels of GREM1 and reduced levels of BMP4 as the ovary develops in vivo may act to reduce LGR5 levels and allow pre-granulosa cell
differentiation.
LIMITATIONS, REASONS FOR CAUTION:While we have demonstrated that markers of different somatic cell types are expressed in
the cultured ovarian somatic cells, their proportions may not represent the same cells in the intact ovary which also contains germ cells.
WIDER IMPLICATIONS OF THE FINDINGS: This study extends previous work identifying germ cells as targets of ovarian BMP signal-
ling, and suggests BMPs may regulate the development of both germ and somatic cells in the developing ovary around the time of follicle
formation.
LARGE SCALE DATA: Not applicable.
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Introduction
Female reproductive lifespan is determined before birth, with the for-
mation of a pool of primordial follicles within the fetal ovaries, which
constitute the supply of eggs for her entire life. In mammals, primordial
follicle formation results from a highly dynamic period of germ and
somatic cell reorganisation within the ovary. This occurs during fetal
life in humans, and around the time of birth in mice. The size of the
primordial follicle pool is determined by a mixture of germ cell prolifer-
ation and apoptosis, and interactions with surrounding somatic cells
(Findlay et al., 2015), mediated by juxtacrine, paracrine and endocrine
factors within the ovary. In mice, follicle formation occurs in two dis-
tinct waves (Mork et al., 2012, Zheng et al., 2014), with an early popu-
lation of follicles assembled in the medulla which support puberty and
the early phases of fertility, and second cohort formed in the cortex,
which supports long-term female fertility.
The somatic cells which contribute to these different follicular
cohorts also appear to be distinct. Somatic cells expressing the tran-
scription factor Foxl2 are found in the medullary region, and form the
pre-granulosa cells of the first wave of medullary primordial follicles
(Mork et al., 2012; Zheng et al., 2014). Leucine-rich repeat-containing
G-protein coupled receptor 5 (LGR5; a known marker of adult stem
cells (Hirsch et al., 2014, Ng et al., 2014)) is expressed by somatic
cells in the cortical region of fetal and postnatal mouse ovary, and
LGR5-positive cells appear to be the progenitors of the pre-
granulosa cells of follicles which form in the ovarian cortex (Rastetter
et al., 2014). A third population of cells, expressing nuclear receptor
subfamily 2 group F member 2 (NR2F2) (also known as COUP
transcription factor 2, COUPTFII), may be of mesenchymal origin
and contribute to the theca cell population as follicles grow
(Rastetter et al., 2014), and are possibly equivalent to vascular
associated somatic cells labelled by transcription factor MafB (MAFB)
(Maatouk et al., 2012). The intrinsic and extrinsic mechanisms
governing the specification and maintenance of these different
populations of somatic cells remains to be established, however their
distinct spatial distributions may support a role for localised growth
factor signalling in regulating their ontogeny.
Bone Morphogenetic Proteins (BMPs) are critical regulators of ovar-
ian development and function. BMP4 is required for primordial germ
cell (PGC) specification, migration and maintenance (Pangas, 2012),
and may contribute to the regulation of follicle growth. Bmp2 expres-
sion is restricted to the fetal mouse ovary after sex determination, and
its expression is driven by WNT signalling (Yao et al., 2004). BMP2
expression was also detected in the somatic cells of the developing
hamster ovary around the time of follicle formation (Chakraborty and
Roy, 2015), and culture of feto-neonatal hamster ovaries with recom-
binant BMP2 reduces apoptosis and promotes primordial follicle for-
mation, possibly by promoting the transition of mitotic germ cells into
meiotic oocytes (Chakraborty and Roy, 2015). In humans, levels of
BMP4 transcripts fall across gestation as germ cells enter meiosis, while
levels of BMP2 rise (Childs et al., 2010), and culture of human fetal
ovaries with BMP4-induced germ cell apoptosis (Childs et al., 2010).
We have previously reported that BMP4 levels fall and BMP2 levels
rise in the human fetal ovary with increasing gestation, while expres-
sion of the two Type I BMP receptors and their activated downstream
mediator pSMAD1/5/8 appeared to be predominantly in germ cells.
Weak staining for BMP receptor 1A (BMPR1A) was detected in the
somatic cells of 9-week ovaries, however, suggesting these two may
be possible cellular targets of BMP activity (Childs et al., 2010).
Whether the BMP pathway is active in human ovarian somatic cells
has yet to be explored.
BMP pathway activity is regulated at a number of levels. Extracellular
antagonists, including members of the DAN/Cerberus family (Walsh
et al., 2010), bind BMPs and prevent them from associating with their
receptors. These include GREMLIN (GREM1), its closely related homo-
logue GREM2 (also called PRDC) as well as NOGGIN (NOG) and
CHORDIN (CHRD). Disruption of Grem1 in mice leads to reduced
oocyte numbers, delayed meiotic progression as well as delayed primor-
dial follicle formation at the neonatal stage (Myers et al., 2011), suggest-
ing that limiting BMP activity is important for the timely assembly of
primordial follicles. CHRD and NOG are expressed predominantly in
the granulosa cell compartment of small and growing follicles in cattle,
and ex vivo experiments suggest that they contribute to intra-follicular
BMP and activin signalling (Glister et al., 2011). In addition to these
extracellular regulators of BMP activity, intracellular inhibitory SMADs
(I-SMADs, SMADs 6 and 7) act to block SMAD1/5/8 phosphorylation,
and/or nuclear translocation. SMAD6 is strongly expressed in the
oocytes of primordial follicles in the mouse, and only weakly expressed
in growing follicles or somatic cells (Gueripel et al., 2004) but is
expressed by somatic cells surrounding developing germ cells in the
human fetal ovary (Childs et al., 2010).
While it is clear that BMP signalling is involved in human ovarian
development, the potential implications of the apparent switch from a
BMP4 to a BMP2-predominant environment and the presence and
functional roles of BMP antagonists has not been explored. Here we
examined the expression of a number of extracellular BMP antagonists
in the human fetal ovary and utilised culture of primary human fetal
ovary somatic cells to characterise the BMP pathway in these cells and
examine the possible roles of GREM1 and GREM2 in regulating this
pathway. To determine whether BMPs may play a role in the specifica-
tion or development of ovarian somatic cells, we also examined
whether expression of somatic cell markers LGR5 and FOXL2 were
modulated by BMPs or GREM1/2 in the cultured somatic cells.
Materials andMethods
Collection of human fetal ovaries
Ovaries were obtained from morphologically normal human fetuses (8–21
weeks gestational age) following medical termination of pregnancy.
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Written informed consent was obtained in accordance with national guide-
lines, and with ethical approval from Lothian Research Ethics Committee
(Study Code LREC 08/S1101/1). Gestational age was measured by ultra-
sound scan before the procedure and confirmed by measuring foot length
afterwards. Ovaries were removed and either snap frozen and stored at
−80°C for subsequent extraction of RNA or protein, or placed in Hanks
Buffered Salt Solution (HBSS; Sigma-Aldrich, Dorset, UK) for disaggrega-
tion and isolation of ovarian somatic cells as described below. A total of 26
fetal ovary specimens and 6 primary ovary somatic cell cultures were used
in this study.
Derivation of primary human fetal ovary
somatic cell cultures
Each ovary was cleaned of extraneous tissue in HBSS and then placed, one
ovary at a time, onto a dimple slide with 50 µl of 10 mg/ml Collagenase
Type IV (Sigma-Aldrich; C1889-50MG) in HBSS and pulled apart with 19G
needles. The tissue fragments and liquid were transferred to a 1.5 ml tube
and the slide washed with a further 100 µl of collagenase solution, which
was pooled with the tissue suspension. This procedure was repeated with
the second ovary, the tissue pooled with that of the first ovary, and com-
bined with the remainder of the 500 µl collagenase stock. The tissue/col-
lagenase mix was incubated in a Thermomixer (Eppendorf, Stevenage, UK)
at 37°C for 10 min with regular pipetting to ensure complete disaggrega-
tion of the tissue. 50 µl of DNase I (7 mg/ml stock in HBSS; Sigma Aldrich;
DN25-100MG) was added and incubation continued for a further 5 min at
37°C. The cell suspension was then spun down at 500 g for 5 min in a
micro-centrifuge, and the pellet washed twice in 1 ml HBSS. After the
second wash, the pellet was re-suspended in 1 ml of somatic cell culture
medium (SCCM; Dulbecco’s Modified Eagles Medium (DMEM; w/o phe-
nol red)/10% Fetal Bovine Serum (FBS)/2 mM L-glutamine/1×MEM Non-
Essential Amino Acids (NEAA)) with 1× penicillin/streptomycin/ampho-
tericin (P/S/A) added (all Life Technologies, Paisley, UK). The suspension
was filtered through a 70 µm filter in a 50 ml Falcon tube, transferred into a
fresh 1.5 ml tube, spun down again and re-suspended in 1.2 ml SCCM.
Two hundred microliter of the cells were transferred to another 1.5 ml
tube, spun down, washed in Dulbecco’s PBS (DPBS, Life Technologies)
and re-suspended in 350 µl of RLT Buffer (Qiagen, Crawley, UK) contain-
ing 143 mM 2-mercaptoethanol (2-ME, Sigma-Aldrich) and stored at
−80°C. These cells were used to make RNA (0 timepoint) for cell charac-
terisation by qRT-PCR. The remaining cells were split over 2 wells of a 12-
well plate, and each well made up to 1 ml with SCCM. Cells were incu-
bated at 37°C/ 5% CO2 in air overnight to allow separation of somatic
and germ cells by differential adhesion to the plate surface. Next day, cul-
ture supernatant containing germ cells, dead cells and other debris was
removed and the adherent somatic cells washed three times in SCCM.
This process was repeated again the next day to remove residual germ
cells. Once cells were confluent, they were passaged by trypsinisation and
re-plated in larger wells until sufficient to be placed in cell culture flasks. At
this stage a portion of the cells were spun down and re-suspended in 1 ml
Bambanker (Anachem, Beds., UK) for cryopreservation. A total of six cell
cultures (Table I) were derived and used in this study and could be pas-
saged at least 12 times. At each of the earlier passages, a small aliquot of
cells was lysed in RLT+2-ME for RNA extraction in order to allow charac-
terisation of expressed marker genes by qRT-PCR.
Treatment of primary human fetal ovarian
somatic cell cultures with recombinant
growth factors and antagonists
Human fetal ovarian somatic cells were cultured in SCCM and passaged
until there were sufficient cells for each experiment. Cells for treatments
were used at passages 5–10. Cells were plated in 24 or 12-well plates (for
RNA extraction) or 6-well plates (for protein extraction) to give ~80%
confluency the next day (approximately 1 × 105 cells/cm2 of culture area),
and were then washed three times in DPBS before starving in serum-free
SCCM overnight. Treatments and appropriate vehicle controls (Table II)
were prepared in serum-free SCCM and applied to the cells for the appro-
priate time (24 h for RNA extraction or 1 h for pSMAD phosphorylation
determination).
Extraction of RNA and first strand cDNA
synthesis
RNA was extracted from frozen fetal ovaries using the RNeasy Mini Kit
(Qiagen; specimens over 12 weeks) or RNeasy Micro Kit (Qiagen; speci-
mens at 8–11 weeks and RLT lysates of treated cell extracts) with
on-column DNase I digestion, according to the manufacturer’s protocols.
RNA concentration and purity was measured on the NanoDrop 1100
(NanoDrop Products, Wilmington, DE, USA) and first strand cDNA
synthesised from 500 ng RNA (ovaries or cell treatments) or 200 ng RNA
(early cell passages) using the Maxima First Strand cDNA Synthesis Kit
(Fisher Scientific, Loughborough, UK) +/− the RT enzyme mix (RT+ and
RT− respectively) according to the manufacturer’s recommendations.
QRT-PCR
Quantitative reverse transcriptase-PCR (qRT-PCR) was performed in
10 μl Reactions of 1× Brilliant III SYBR green Mastermix (Agilent
Technologies, Stockport, UK) containing 500 nM each of relevant forward
and reverse primers (Supplementary Table 1), 2 μl of a 1/20 dilution of
each cDNA and 300 nM of passive Reference Dye (provided with the kit)
for the ABI 7900HTFast Thermocycler (Life Technologies). Cycling condi-
tions of 95°C for 3 min followed by 40 cycles of 95°C for 5 s and 60°C for
15 s were used, as recommended by the manufacturer. For each gene of
interest, each RT(+) sample was analysed in triplicate, and a single RT(−)
reaction performed as a negative control. Melt curve analysis of each run
confirmed expected product sizes, and standard curves for each set of pri-
mers were derived using increasing dilutions of FT3010 fetal ovarian som-
atic cell cDNA to determine amplification efficiency. Threshold values (Ct)
and gradients of standard curve slopes determined the concentration of
each gene of interest in each test sample. Gene-of-interest expression was
normalised to that of the housekeeping gene RPL32, which remained stable
across gestation and between treatments.
RT-PCR and agarose gel analysis of BMP
receptors
Expression of BMP receptors in human fetal ovary and fetal ovary somatic
cell cultures was assessed by end-point RT-PCR of RNA from fetal ovary
........................................................................................
Table I Human fetal ovarian somatic cell cultures.
Cell Culture Gestation of Ovaries
FT2692 16 weeks + 1 day
FT3010 15 weeks + 1 day
FT3096 9 weeks + 2 days
FT3329 17 weeks + 5 days
FT3330 14 weeks + 5 days
FT3331 16 weeks + 1 day
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RNA and RNA from 9, 15 and 17 week ovary somatic cell lines.
RT- controls were also included. Reactions contained 500 nM each of
each primer (Supplementary Table 1) and 1 µl of a 1/6 dilution of each
cDNA (or water) in a 25 µl volume in 1× MyTaq HS Red Mastermix
(Bioline, London, UK). 2-step reaction conditions were 95°C for 1 min.
followed by 35 cycles of (95°C, 5 s/ 60°C, 20 s) in a PTC-100
Thermocycler (MJ Research). 10 µl of each reaction was electrophor-
esed alongside 100 bp DNA Ladder markers (Bioline) through a
2.5% agarose/ 1× Tris/Acetate/EDTA gel containing a 1/10 000 dilu-
tion of GelRed (Cambridge Biosciences, Cambridge, UK) and imaged
under UV transillumination on a UGENIUS gel documentation system
(Syngene Europe, Cambridge, UK).
Protein extraction
Protein was extracted from fetal ovaries by homogenisation in 100 µl 1×
RIPA Buffer (25 mM Tris.HCl, pH7.5; 150 mM NaCl ; 0.1% (v/v) SDS; 1%
(v/v) Triton-X100; 0.05% (w/v) sodium deoxycholate and Mini Complete
protease and phosphoSTOP phosphatase inhibitors (Roche)), using a
Pellet Pestle (Sigma-Aldrich), or from cells in 6-well plates by washing twice
in DPBS before lysis in 250 µl 1× RIPA Buffer and transferring the lysate
into a 1.5 ml micro-centrifuge tube on ice. All lysates were spun at 14 000 g
for 10 min at 4°C and the supernatants transferred to fresh tubes on ice.
Protein concentrations were determined using the Bio-Rad DC Protein
Assay (Bio-Rad Laboratories Ltd., Herts., UK).
Western blotting and band quantification
Twenty µg (for GREM1) or 10 μg (for pSMAD1/5/8) of protein lysates
were mixed 3:1 with 4× SDS sample buffer (250 mM Tris.HCl, pH6.8;
40% (v/v) Glycerol; 4% (w/v) SDS; 0.02% (w/v) Bromophenol Blue with
15% (v/v) 2-ME added just prior to use), denatured at 99°C for 6 min,
then loaded alongside 5 µl of PageRuler Plus Prestained Protein Ladder
(Fisher Scientific) on 12 well 4–20% Mini-Protean TGX gels, run in
1×Tris/Glycine/SDS buffer (both Bio-Rad). Gels were rinsed twice in
water for 5 min, equilibrated for 10 min in Pierce 1× Methanol – free
Western Blot Transfer Buffer (Fisher Scientific) then blotted onto
Immobilon-FL PVDF membrane (Millipore UK Ltd., Watford, UK) using a
Pierce Semi-dry Blotting Apparatus (Fisher Scientific) for 9 min at 25 V.
Membranes were blocked in Rockland Fluorescent Blocking Buffer
(Tebu-Bio Ltd, Peterborough, UK) diluted 1:1 in PBS containing 0.1%
Tween20 (PBST) for an hour. Primary antibodies (Supplementary
Table 2) were diluted as indicated in 1:1 blocking buffer: PBST, and then
incubated with the blots at 4°C overnight with shaking. Blots were
washed four times in PBST, for 5 min each, and incubated in the dark for
1 h with dilutions of Infrared Dye-labelled anti-rabbit and anti-mouse sec-
ondary antibodies as indicated in Supplementary Table 2. After washing
twice each in PBST and then PBS, blots were imaged on a LiCor Odyssey
Infrared Scanner, using Image Studio 5.0 Software. The pSMAD1/5/8
blot was quantified by drawing equal sized rectangles around individual
bands and allowing the software to detect the total fluorescence signal
minus background at the relevant wavelength. pSMAD1/5/8 signals
were normalised to β-actin in the sample.
Statistical analysis
Fetal ovary gene expression data were not normally distributed and
so were analysed by Kruskal–Wallis Test with Dunn’s Multiple
Comparisons post-hoc test. QRT-PCR data on cell culture treatments,
which showed a normal distribution, were analysed by one-way
ANOVA with Tukey’s Multiple Comparisons post-hoc test. All ana-
lyses were performed using GraphPad Prism 6.0 software.
Results
Expression of BMP antagonists during human
fetal ovarian development.
Expression of BMP antagonists NOG, GREM1, GREM2, CHRD, SMAD6
and SMAD7 was examined by qRT-PCR using cDNA samples corre-
sponding to three stages of human fetal ovarian development, namely:
8–11 weeks (post-migratory germ cell proliferation), 14–16 weeks
(entry of germ cells into meiosis) and 17–21 weeks (start of primordial
follicle formation) (Fig. 1). Levels of GREM1 mRNA increased 17-fold
(P ≤ 0.05) between 8–11 and 14–16 weeks and this level was main-
tained at 17–21 weeks. GREM2 expression increased 5-fold between
8–11 and 14–16 weeks gestation (P ≤ 0.05) and, as for GREM1, there
was no further increase in GREM2 between 14–16 and 17–21 weeks
gestation. CHRD transcript levels increased more gradually, with
expression rising 2.4 fold between 8–11 and 17–21 weeks (P ≤ 0.05).
No significant change was detected in SMAD6 or SMAD7 levels across
gestation. NOG transcripts were also detected (not shown), but at a
level too low to permit accurate quantification.
Human fetal ovarian somatic cells express
somatic cell markers and components of the
BMP signalling pathway in vitro
To permit the functional analysis of BMPs and their antagonists in fetal
ovary somatic cells, a number of primary ovarian somatic cell cultures
(Table I) were derived from disaggregated human fetal ovaries by dif-
ferential adhesion to cell culture plastic. The cultures had a fibroblast-
like appearance and expanded continuously for at least 12 passages
.............................................................................................................................................................................................
Table II Cell treatments.
Treatment Source Cat. No. Vehicle Stock
Conc.
Working Conc.
Recombinant Human BMP4 Life Technologies (Paisley, UK) PHC-9534 4 mM HCl/ 0.1% BSA in PBS 10 μg/ml 1–100 ng/ml as indicated in text
Recombinant Human BMP2 Life Technologies (Paisley, UK) PHC-7145 4 mM HCl/ 0.1% BSA in PBS 100 μg/ml 1–100 ng/ml as indicated in text
Recombinant Human
Gremlin, CF
R&D Systems (Abingdon, UK) 5190-GR-050 PBS 200 μg/ml 1 μg/ml
Recombinant Human
PRDC/GREM2, CF
R&D Systems (Abingdon, UK) 8436-PR-050 4 mM HCl in PBS 500 μg/ml 100 ng/ml
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with a doubling time of 24–36 h. Passaging was necessary in order to
derive sufficient cells on which to perform the experiments and to
enable further experiments as data were obtained. Expression of ovar-
ian somatic and germ cell markers was determined by qRT-PCR to
assess changes with passage (Fig. 2). Expression of the germ cell
marker DAZL was undetectable within two passages in each of the cell
cultures, indicating germ cells were lost rapidly from the cultures (simi-
lar results were obtained with the germ cell markers POU5F1 and
VASA; data not shown). In contrast, expression of the somatic cell mar-
kers FOXL2, NR2F2 (COUPTFII) and LGR5 were retained with
increasing passage number indicating that dedifferentiation was not
occurring to a major extent. Levels of the BMP response gene ID2,
which is expressed in somatic cells in human fetal ovary (unpublished
data), remained fairly constant across passages in each of the cell cul-
tures at least up to passage 5. BMP4 transcripts showed a decline
with passage although remained readily detectable. GREM1 expres-
sion tended to increase, and GREM2 was also detectable throughout,
although it was more variable. In summary, the cultures show signifi-
cant phenotypic similarity and stability in their expression profiles,
despite being derived from ovaries from fetuses of different gesta-
tional ages.
We also determined expression of the BMP receptor genes
(BMPR1A, BMPR1B and BMPR2) in fetal ovarian somatic cell cultures
and across gestation in human fetal ovary by RT-PCR. Specific bands
of the expected size were obtained for all three receptors (Fig. 3A).
Expression of GREM1 protein in fetal ovary and ovarian somatic cells
was demonstrated by western blotting, with anti-β-actin as a positive
control for protein integrity. A band of the appropriate size (approxi-
mately 30 kDa) was detected in all ovary and somatic cell extracts
(Fig. 3B).
BMP signalling is functional in human fetal
ovarian somatic cell lines and sensitive to
GREM1
Expression of BMP receptors and antagonists in human fetal ovary som-
atic cell cultures suggested that the BMP pathway may be functional
within these cells. To test this hypothesis, two independent somatic
cell cultures (derived from 9 weeks (FT3096) and 15 weeks (FT2692)
ovaries) were treated for 1 h with either (i) vehicle, (ii) 1 µg/ml
recombinant human GREM1 (iii) 50 ng/ml recombinant human
BMP4 or (iv) 50 ng/ml recombinant human BMP4 and 1 µg/ml recom-
binant human GREM1. Western blotting indicated that there was negli-
gible pSMAD1/5/8 signal in extracts of vehicle or GREM1-treated cells
from both the 9- and 15-week cultures, but BMP4 treatment for 1 h
resulted in a 36-fold increase in pSMAD1/5/8 levels in FT3096 (9
weeks) and a 23-fold increase in FT2692 (15 weeks) cell lysates
(Fig. 3C,D). This effect was reduced, but not completely abolished,
when cells were treated with a combination of GREM1 and BMP4.
These data indicate that human fetal ovarian somatic cells display the
Figure 1 QRT-PCR Analysis of bone morphogenetic protein (BMP) antagonist expression across gestation in the human fetal ovary. Expression
levels of each gene are given, normalised to the level of RPL32 in each sample. Ovary gestations are grouped to represent different stages in develop-
ment as described in the main text. Results for individual samples (n = 5–6 for each stage) are presented along with median values. Changes between
stages were analysed by the Kruskal–Wallis Test with Dunn’s multiple comparisons and different letters above groups represent statistically significant
differences (p ≤ 0.05, or less as indicated in the main text).
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ability to receive and transduce BMP signals, and that this signalling can
be antagonised by GREM1.
BMPs 2 and 4 exert differential effects on
gene expression in human fetal ovarian
somatic cells
In the human fetal ovary, BMP4 expression decreases across gestation
while BMP2 mRNA levels increase, suggesting that these two BMPs
might have different functional roles during ovarian development
(Childs et al., 2010). This was investigated by comparing the effect of
treatment with BMP2 or BMP4 on gene expression in human fetal
ovarian somatic cells (FT2692 from 15-week ovary) (Fig. 4). ID genes
are known immediate downstream targets of BMPs in other systems,
and we observed an increase in ID2 of up to 12-fold at concentrations
≥10 ng/ml of BMP4. Although there seemed to be a small increase in
ID2 at higher concentrations of BMP2, this did not reach significance.
BMP4-treatment induced a decrease in BMP4 gene expression (of up
to 4-fold), although this was only significant at BMP4 concentrations
≥50 ng/ml, while BMP2 had no significant effect on BMP4 gene
expression. Treatment with either BMP2 (100 ng/ml) or BMP4
(≥10 ng/ml) resulted in significantly increased BMP2 gene expression
(up to 3-fold P < 0.05). Expression of GREM1 increased in response to
treatment with either BMP, rising 5-fold at ≥10 ng/ml BMP4 and over
2-fold at ≥50 ng/ml BMP2. GREM2 expression was sensitive only to
BMP4 treatment, rising up to 100-fold with BMP4, while BMP2 had no
effect. There was no significant effect of either BMP on the expression
of SMAD1 or SMAD5.
We also examined the effect of BMPs 2 and 4 on the expression of
key somatic cell markers in ovarian somatic cell cultures. Strikingly, we
found that BMP4 treatment induced increases of up to 20-fold in the
expression of LGR5, at concentrations ≥10 ng/ml (small increases in
LGR5 expression at ≥50 ng/ml BMP2 were not significant). This iden-
tifies LGR5 as a novel transcriptional target of BMP signalling in the
Figure 2 Expression of germ cell and various somatic cell markers with passage of adherent cells following disaggregation of human fetal ovaries.
Expression of the germ cell marker DAZL, markers of differentiating pre-granulosa cells (FOXL2), steroidogenic cell precursors (NR2F2), immature div-
iding pre-granulosa cell precursors (LGR5) and components of the BMP pathway (ID2, BMP4, GREM1 and GREM2) were examined by qRT-PCR across
passages for a number of human fetal ovarian somatic cell cultures derived from 14 to 17 week disaggregated ovaries (n = 5 for DAZL, FOXL2, NR2F2
and ID2; n = 4 for BMP4; n = 3 for LGR5, GREM1 and GREM2). Results are expressed as mean expression relative to RPL32 ± sem. The 0 time point
represents disaggregated ovaries prior to plating.
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developing human fetal ovary. Neither BMP2 nor 4 had any significant
effect on expression of FOXL2 or NR2F2 transcript levels, indicating
the effect on LGR5 to be specific.
In view of this finding, changes in LGR5 expression were investigated
across gestation by qRT-PCR. LGR5 mRNA levels fell from 57.8 ±
18.5 pmol/nmol RPL32 at 8–11 weeks gestation to 12.0 ± 5.5 at
14–16 weeks, are remained at a similar level at 17–21 weeks
(11.7 ± 5.9 pmol/nmol RPL32; P = 0.005, n = 6 per group).
GREM1 and GREM2 antagonise the effects of
BMP4 on transcription in a gene-specific
manner
Having demonstrated that GREM1 can inhibit phosphorylation of
SMAD1/5/8 in response to BMP4, and that a number of genes
expressed in ovarian somatic cells are BMP-sensitive, we next tested
whether GREM1 could affect expression of genes regulated by BMP4,
either alone or in combination with BMP4. Human fetal ovarian som-
atic cells were treated with vehicle, 1 µg/ml recombinant human
GREM1, 50 ng/ml recombinant human BMP4 or both BMP4 and
GREM1 in serum-free medium for 24 hours, and expression of key
transcripts analysed by qRT-PCR (Fig. 5).
Treatment with GREM1 alone had no significant effect on any of the
genes examined. BMP4 alone led to a 15-fold increase in expression of
ID2, and this increase was abolished completely by the addition of
GREM1. GREM1 reduced, but did not abolish, the inhibitory effect of
BMP4 treatment on BMP4 expression, but had no effect on the stimu-
lation of BMP2 expression by BMP4. The effects of BMP4 treatment
on BMPR2, SMAD1, SMAD7 and GREM2 (either stimulatory or inhibi-
tory) were also prevented by GREM1, whereas GREM1 did not inhibit
Figure 3 Components of the BMP signalling pathway are expressed in human fetal ovary and cultured ovarian somatic cells and regulate SMAD1/5/
8 phosphorylation. A: Agarose gel analysis of RT-PCR products for the 3 BMP receptors (BMPR1A, BMPR1B, BMPR2). M is the 100 bp Hyperladder
(Bioline). (+) and (−) represent reactions with RT(+) and RT(−) cDNAs respectively. Gestations of fetal ovaries and derived somatic cell cultures
used are given in weeks (wk). T0 is cells from ovary disaggregation prior to plating (i.e. contains both germ and somatic cells), P0 is adherent somatic
cells taken just prior to the first passage and P2-4 represents the number of passages undergone for each cell culture. B: Western blot analysis of
GREM1 expression. M is the PageRuler Plus (10–250 kda) Prestained Protein Ladder (Fisher Scientific) and numbers beside individual marker bands
give their MW as a guide. GREM1 (lower bands) with β-actin (upper bands) acting as a positive control. C: Western blot of protein extracts from cells
(cultures FT3096 and FT2692) treated with vehicle (V), recombinant GREM1 (G), recombinant BMP4 (B) or BMP4 + GREM1 (BG) for 1 hour after
overnight serum-starvation. M is the PageRuler Plus (10–250 kda) Prestained Protein Ladder (Fisher Scientific) and white numbers over individual bands
indicate their MW. pSMAD1/5/8 signal (expected MW = 60) is red while the β-actin normalisation control (expected MW = 42) signal is green.
D: Comparison of pSMAD1/5/8 levels normalised to β-actin signal for each treatment and cell culture (single replicates only performed).
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the stimulation of expression of GREM1 gene expression by BMP4. It
was not possible to analyse properly the effects of treatments on LGR5
expression in FT3010 cells as expression was so low in vehicle,
GREM1 and BMP4 plus GREM1-treated cells that it was not reliably
detectable although it was readily detectable in BMP4 treated FT3010
cells (data not shown), confirming our earlier result that LGR5 is
BMP4-responsive in culture FT2692 (Fig. 4). Since addition of GREM1
to BMP4 led to unreliable LGR5 detection, this BMP4 effect also
appears to be GREM1 sensitive.
GREM2 is also expressed in human fetal ovary and ovarian somatic
cells, and is up-regulated by BMP4, therefore we also examined pos-
sible interactions between recombinant GREM2 with BMP4 in an ovar-
ian somatic cell line (Fig. 6). As with GREM1, addition of GREM2 alone
had no effect on any genes examined, but displayed a similarly variable
capacity to antagonise the effects of BMP4 on gene expression.
GREM2 was effective at reducing the magnitude of the BMP4-induced
increases in ID2 and GREM2 expression, but did not affect the respect-
ive decrease and increase of BMP4 and GREM1 expression in response
to BMP4 treatment. The effect of GREM2 on the BMP4-induced stimu-
lation of LGR5 expression was also examined, but found to be ineffect-
ive (despite similarities in the level of BMP4-induced LGR5 expression
in the two cell cultures examined) which were generally higher for
other induced genes in FT3010 cells than in FT3330, which is from a
similar gestation.
Discussion
BMP signalling can be regulated by a range of inhibitory factors, both
intracellular and extracellular (Walsh et al., 2010), which provide
mechanisms to limit the intensity and/or physical range of BMP signals. In
the mouse, the BMP antagonist, GREM1 is required for the timely assem-
bly of primordial follicles, indicating that restraining the intensity of BMP
signalling is important for follicle formation to proceed (Myers et al.,
2011). While BMPs are known to be expressed in the developing human
ovary (Childs et al., 2010), the presence of their antagonists has not been
examined. In this report, we investigated the expression of a number of
BMP antagonists in the human fetal ovary, in cultures of ovarian somatic
cells, and their functional ability to antagonise BMP-induced changes in
gene expression. Human fetal ovarian somatic cells were shown to be
more sensitive to BMP4 than BMP2, and GREM1 and GREM2 were
shown to antagonise some but not all effects of BMP4 on these cells.
This indicates the involvement of these regulatory pathways in human
ovarian development, and that the modulation of BMP signalling by
Figure 4 Titration of BMP4 and BMP2 effects on downstream gene expression in human fetal ovarian somatic cells. FT2692 ovarian somatic cells
were serum-starved overnight and then treated (2 replicate wells per treatment) with vehicle or 1, 10, 50 or 100 ng/ml of recombinant human BMP4
or BMP2 for 24 h and RNA extracted. QRT-PCR for the genes indicated was performed and normalised to levels of RPL32 before calculating fold
changes relative to the vehicle control. Data points are mean ± sem. BMP2 treatment graphs are blue while BMP treatment graphs are red. Data were
analysed by ANOVA with Tukey’s multiple comparisons post-hoc tests and significant differences (P ≤ 0.05) between treatment concentrations are
indicated by different letters (with colour matching key) above the relevant concentration.
629BMP action in human fetal ovary somatic cells
 at R
oyal V
eterinary College on Septem
ber 9, 2016
http://m
olehr.oxfordjournals.org/
D
ow
nloaded from
 
GREM1 and GREM2 is more complex than simply limiting it, but rather
provides a mechanism whereby BMP responses become more selective.
The expression of BMP antagonists was demonstrated in both nor-
mal fetal ovary across a range of gestations, and in isolated somatic
cells. Expression of the genes encoding the related extracellular
antagonists GREM1, GREM2 and CHRD increased with gestation, sug-
gesting that they have roles in BMP signalling during human ovary
development in the lead-up to follicle formation. While these antago-
nists are best characterised for their interactions with BMP signalling,
other functions for GREM1 have also been identified, including regula-
tion of chemotaxis via Slit proteins (Chen et al., 2004) and by binding
to heparin proteoglycans on the cell surface to enhance angiogenesis
(Chiodelli et al., 2011). BMP/GREM interactions were further
explored by isolating and characterising a number of primary human
fetal ovarian somatic cell cultures, to allow functional studies not
possible in organ culture. These cultures become rapidly devoid of
germ cell markers, but they retain expression of the somatic cell mar-
kers LGR5, FOXL2 and NR2F2. LGR5 expression was quite variable,
while FOXL2 levels fell initially and then levelled off and NR2F2 levels
remained fairly constant in each cell line.
We have shown previously, by immunohistochemistry, that
BMPR1A and BMPR1B, as well as pSMAD1/5/8 are predominantly
expressed by germ cells in the human fetal ovary (Childs et al., 2010).
Using RT-PCR, we have now demonstrated that BMP receptors are
expressed not only in intact human fetal ovary but also in isolated
ovarian somatic cells from the earliest passages and that these recep-
tors function to promote BMP signalling through phosphorylation of
SMAD1/5/8. While it is possible that expression of BMP receptors in
the somatic cells was acquired or increased during culture, we have
previously reported expression of BMPR1a in the somatic cells of the
Figure 5 GREM1 sensitivity of BMP4 target genes in human fetal ovarian somatic cells. FT3010 cells were serum-starved overnight and treated
with ± 1 µg/ml GREM1, ± 50ng/ml BMP4 (n = 4 replicate wells for each treatment) for 24 hours before RNA extraction and qRT-PCR analysis of key
BMP4 targets, with normalisation to RPL32 transcript levels. Columns represent mean ± sem for each treatment (white = vehicle, red = GREM1,
blue = BMP4, purple = BMP4 + GREM1). Differences in expression levels between treatments were analysed by ANOVA with Tukey’s multiple com-
parisons post-hoc tests and significant differences (P ≤ 0.05 or less, as indicated in the main text) between treatments are indicated by different letters
above the columns, or * in the case of SMAD1 (P = 0.01).
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9 weeks human fetal ovary (Childs et al., 2010), and it is possible that
low-levels of BMP receptor or pSMAD1/5/8 expression in somatic
cells at later developmental stages may have gone undetected due to
the stronger immunohistochemical signal from these antigens seen in
germ cells. We also demonstrate expression of a number of intracellu-
lar and secreted BMP antagonists in the fetal ovary which are tran-
scribed in the somatic compartment. Germ cell expression of these
antagonists is also possible, but remains unexplored.
BMP4 and, to a lesser extent BMP2, altered expression of genes
involved in BMP signalling within the somatic compartment, including
their own expression and two of their antagonists (GREM1 and
GREM2), providing evidence for positive and negative feedback loops,
and suggesting tight control of BMP signalling within the somatic
compartment to maintain normal growth and development. This tight
regulation is also supported by the demonstration that BMP4 inhibits
its own transcription, while increasing expression of BMP2. BMP2 was
markedly less effective at altering gene expression in the ovarian som-
atic cells, although this could, at least in part, be due to different bio-
logical activities of the recombinant proteins.
As the expression of GREM1 and GREM2 increased with gestation,
we explored the interaction of these extracellular antagonists with the
effects of BMP4 on ovarian somatic cells derived from ovaries of
appropriate gestation. Confirmation of biological activity was provided
by the demonstration that recombinant GREM1 reduced BMP4-
mediated phosphorylation of SMAD1/5/8 in isolated ovarian somatic
cells. Furthermore, GREM1 had a marked effect on the ability of BMP4
Figure 6 GREM2 Sensitivity of BMP4 Target Genes in human fetal ovarian somatic cells. FT3330 cells were serum-starved overnight and treated
with ± 100 ng/ml GREM2, ± 50 ng/ml BMP4 (n = 4 replicate wells for each treatment) for 24 h before RNA extraction and qRT-PCR analysis of key
BMP4 targets, with normalisation to RPL32 transcript levels. Columns represent mean ± sem for each treatment (white = vehicle, red = GREM2,
blue = BMP4, purple = BMP4 + GREM2). Differences in expression levels between treatments were analysed by ANOVA with Tukey’s multiple com-
parisons post-hoc tests and significant differences (P ≤ 0.05 or less, as indicated in the main text) between treatments are indicated by different letters
above the columns.
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to alter expression of a number of genes (ID2, BMPR2, SMAD1,
SMAD7 and GREM2, and possibly also LGR5) expressed by ovarian
somatic cells. GREM1 was able to prevent both stimulatory (ID2,
GREM2) and inhibitory (e.g. SMAD1, BMPR2) effects of BMP4.
Similarly, GREM2 was also able to inhibit the stimulatory effect of
BMP4 on ID2 and GREM2 expression although genes which are inhib-
ited with BMP4 were not tested for the effects of GREM2. However
intriguingly, not all effects of BMP4 were prevented or reduced by
GREM1 or GREM2; changes in the expression of BMP4 and GREM1
were not antagonised by GREM1/2 protein, and nor was BMP2 (at
least in the presence of GREM1). Differential effects of GREM1 and
GREM2 were demonstrated on BMP4 stimulated LGR5 expression,
which was insensitive to GREM2 but appeared to be sensitive to
GREM1, although a lower concentration of GREM2 was used (using
the manufacturer’s recommended working concentrations). Overall,
these results are in keeping with the suggested role of GREM1 in limit-
ing BMP function during primordial follicle formation in the mouse
ovary (Myers et al., 2011), but with a hierarchy of genes in terms of
their sensitivity to blockage of BMP4 function in the presence of
GREM1 or GREM2. It is possible that this reflects different affinities for
pSMAD1/5/8 on different promoters when BMP4 activity is limiting,
with GREM1 and BMP4 genes having the highest affinity for
pSMAD1/5/8, in order to maintain the feedback loop and tight
control of BMP signalling activity. This may serve to provide a mech-
anism of selectivity of BMP action on the somatic compartment of
the developing ovary. In turn this may ‘fine-tune’ the functional activ-
ity of the BMP system in relation to other signalling pathways: cross-
talk with TGFβ signalling is well described in several organs and
tissues, notably in the regulation of tissue fibrosis (Yoshida et al., 2014)
which may be of relevance to ovarian development and disease
(Hatzirodos et al., 2011).
A striking finding of our study is the identification of LGR5, a marker
of undifferentiated somatic cells, as a transcriptional target of BMP signal-
ling in human fetal ovarian somatic cells. This positive regulation of LGR5
by BMP4 was initially surprising given that suppression of BMP signalling
(coupled with active WNT signalling) is required for the renewal of
LGR5-positive intestinal crypt stem cells (Reynolds et al., 2014), while a
switch from inactive WNT/active BMP towards active WNT/inactive
BMP pathways in the Human Intestinal Epithelial Crypt (HIEC) cell line
was sufficient to trigger a robust intestinal stem cell signature, including
predominant LGR5 expression (Guezguez et al., 2014). However, our
result is consistent with BMP4 expression being highest at early stages of
ovarian development during the time of germ cell proliferation, with
reduced expression from the time of onset of meiosis (Childs et al.,
2010) when there is a need for more differentiated pre-granulosa cells
to enable follicle formation to occur, and expression of LGR5 showed
parallel changes with increasing gestation. The absence of an effect of
BMP treatment on the expression of FOXL2 or NR2F2, markers of more
differentiated pre-granulosa cells and stromal cells, respectively, is con-
sistent with this. LGR5 is a G-protein coupled receptor which acts as a
receptor for RSPONDIN to enhance RSPO/WNT/β-catenin signalling.
In the mouse, cells expressing LGR5 lie within and immediately below
the surface epithelium of the developing ovary, and it is believed that, as
they proliferate, they ingress further into the ovary where they up-
regulate Foxl2 and down-regulate Lgr5, thus differentiating into pre-
granulosa cells (Rastetter et al., 2014). How this developmental transi-
tion is established and maintained remains unknown, but it seems likely
that localised spatial differences in the repertoire or intensity of growth
factor signals within different regions of the developing ovary may be
involved. Similarly, in the human fetal ovary, a developmental gradient of
germ cell differentiation is observed, with undifferentiated germ cells
towards the periphery, and progressively more differentiated germ cells
found more centrally, culminating with the formation of the first follicles
deep within the ovary (Fulton et al., 2005). Such differences in the local
growth factor microenviroment required to maintain this gradient would
also impact on somatic cells, possibly influencing their phenotype or
developmental fate depending on their location within the ovary.
Establishing whether there are spatial differences in the expression of
BMPs and their antagonists, LGR5, and FOXL2 within the fetal ovary
may provide insight into this.
In conclusion, these data show the expression of BMP signalling
antagonists in the human fetal ovary. Furthermore, we find that BMP
signalling is active in human fetal ovarian somatic cells in vitro, and can
be modulated by the extracellular antagonists GREM1 and GREM2.
Differential effects of these antagonists may contribute to modulation
of the effects of BMP signalling and provide a mechanism for fine-
tuning of these effects on the somatic compartment of the ovary.
Finally, we reveal that LGR5 is a novel transcriptional target of BMP sig-
nalling in cultured ovarian somatic cells, suggesting possible roles for
BMP signalling in regulating the development of the somatic cell com-
partment in the fetal ovary.
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